CATB


These 3 Biotech Stocks Have Massive Upside Potential, Says Wedbush

Take your eye off the ball, and you might have just missed a home run. Veteran players of the stock picking game know …

Celsion Corporation (CLSN) Wins Over Maxim’s Bullish Blessing, Catabasis Pharmaceuticals Inc (CATB) Has Cowen Encouraged After Promising Pivotal DMD Phase II Trial Results

Celsion strikes iron while its hot to raise $15.6 million; Catabasis slows rate of DMD decline in OLE trial.

Wedbush Shares Two Cents On Catabasis Pharmaceuticals (CATB) Following Clinical Results In DMD

Catabasis Pharmaceuticals (NASDAQ:CATB) investors endured a roller coaster ride in a just a few hours, after the drug maker shared results for Edasalonexent …

H.C. Wainwright Slashes Catabasis Pharmaceuticals Inc (CATB) Price Target in Half, But Sticks with Buy Rating

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares are falling almost 8% amid an unfortunate setback with the firm’s MoveDMD Part B data read-out that failed …

Catabasis Pharmaceuticals Inc (CATB) Is in Rollercoaster Mode

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares are falling 16% today after having just risen approximately 80% last week, placing the biotech stock in full …

Oppenheimer Waits for Catabasis Pharmaceuticals Inc (CATB) to Present Longer Term Data in DMD

Yesterday evening, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced that lead candidate edasalonexent missed the primary endpoint in its Phase II proof-of-concept trial in Duchenne …

Cowen Downgrades Catabasis Pharmaceuticals Inc (CATB), Slashes The Price Target To $4

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares lost over 70% of their value today after the company reported final results from Part B of its …

Cowen Reiterates Upbeat View on Sarepta Therapeutics Inc (SRPT) Amid Pipeline Collaborations

Sarepta Therapeutics Inc (NASDAQ:SRPT) just announced two Duchenne muscular dystrophy (DMD) collaborations to evaluate combotherapy with exon skipping. Sarepta will be partering with …

William Blair Bullish on Sarepta Therapeutics Inc (SRPT) Amid First Patient Dosing in Phase III Trial and Catabasis Partnership

On Wednesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it has dosed the first patient in the Phase III ESEENCE trial for patients with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts